AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. HALO
  4. [SCHEDULE 13G/A] Halozyme Therapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] Halozyme Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source:

Stock HALO logo
Halozyme Thrp

NASDAQ:HALO

HALO Rankings

#1003 Ranked by Market Cap
N/A Ranked by Dividends

HALO Latest News

Aug 28, 2025
Halozyme to Participate at Upcoming Investor Conferences
Aug 5, 2025
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
Jul 23, 2025
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
Jul 22, 2025
Halozyme to Report Second Quarter 2025 Financial and Operating Results
Jun 30, 2025
Halozyme Therapeutics Added to Russell 1000® Index

HALO Latest SEC Filings

Aug 13, 2025
[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity
Aug 5, 2025
[10-Q] Halozyme Therapeutics, Inc. Quarterly Earnings Report
Aug 5, 2025
[8-K] Halozyme Therapeutics, Inc. Reports Material Event
Jul 10, 2025
[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity
Jun 24, 2025
[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity

HALO Stock Data

8.53B
115.60M
1.17%
102.65%
8.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SAN DIEGO